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In cystic fibrosis (CF), chronic respiratory infections result in an exaggerated and
uncontrolled inflammatory response that ultimately lead to a decrease in pulmonary
function. We have previously described the presence of the alarmin IL-33 in lung explants
from CF patients. The signals regulating IL-33 expression in the airway epithelium
following a gram-negative bacterial infection are currently unknown. Our objective was
to characterize the pathways in CF airway epithelial cells (AECs) leading to an increase
in IL-33 expression. We found that, in CF AECs expressing a deletion of a phenylalanine
at position 508 of the gene coding for Cystic Fibrosis Transmembrane Conductance
Regulator (CFTRdelF508), exposure to live Pseudomonas aeruginosa upregulates IL-33
via the TLR2 and TLR5 signaling pathways. This up-regulation can be partially or fully
reverted by pre-incubating CFTRdelF508 AECs with a CFTR corrector (VX-809) and/or a
CFTR potentiator (VX-770). Similarly, incubation with the CFTR corrector and/or the CFTR
potentiator also decreased IL-8 expression in response to infection. Moreover, using
different protein kinase inhibitors that target elements downstream of TLR signaling, we
show that the TAK1→IKKβ→TPL2→MKK1/MKK2 pathway regulates IL-33 expression
following an infection with P. aeruginosa. Our findings represent the first characterization
of the signals regulating IL-33 expression in CF airway epithelial cells in response to a
bacterial infection.
Keywords: MAPK, ERK, Toll-like receptor, airway epithelium, Pseudomonas aeruginosa
Abbreviations: AECs, airway epithelial cells; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator;
DAMPs, damage associated molecular patterns; ERK, extracellular signal-regulated kinase; HMGB1, high mobility group
box 1; IKKβ, I-kappa-B kinase beta; IκB, inhibitor of kappa light polypeptide gene enhancer in B-cells; IL, interleukin;
LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MKK, mitogen-activated protein kinase kinase; Myd88,
myeloid differentiation primary response 88; NF-kB, nuclear factor-kB; NFkB1-p105, nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1; PRR, pattern recognition receptors; PsaDM, Pseudomonas aeruginosa diffusible material; TAK1,
TGF-beta activated kinase 1; TLR, toll-like receptor; TNF, tumor necrosis factor; TPL2, tumor progression locus 2; TRAF6,
TNF receptor-associated factor 6.
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INTRODUCTION
Cystic fibrosis (CF) is a disease caused by mutations in the gene
coding for cystic fibrosis transmembrane conductance regulator
(CFTR), an anion channel expressed in epithelial surfaces
(Riordan, 1989). The role of CFTR is crucial for the transport of
chloride (Cl−) and bicarbonate (HCO−3 ) across cell membranes
(Tabcharani et al., 1997). In the lungs, CFTR malfunction results
in a hyperviscous mucus that is prone to pathogen colonization
(Hoegger et al., 2014). The most prevalent pathogen in adult
CF patients is the bacterium Pseudomonas aeruginosa. In an
effort to clear the infection, airway epithelial cells release several
pro-inflammatory cytokines. This inflammatory response results
in neutrophil recruitment to the respiratory tract, however
this response is often excessive and dysregulated, resulting in
progressive and irreversible lung tissue destruction (Khan et al.,
1995; Dakin et al., 2002). Bronchoalveolar lavage samples from
CF patients with mild lung disease show a marked increase
in neutrophil counts. This, together with increased neutrophil
elastase activity has been shown to directly damage the lung
(Konstan et al., 1994). Several inflammatory mediators have long
been associated with chronic infection, such as interleukin (IL)-6,
CXCL8 (also known as IL-8), tumor necrosis factor alpha (TNF-
α) and granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Dakin et al., 2002; Bérubé et al., 2010). These mediators
are actively released as a result of chronic exposure to bacterial
components. However, tissue damage and cell death caused
by an unbalanced and exaggerated immune response can also
lead to the release of intracellular components that can activate
receptors of the immune system. The latter molecules are known
as Damage Associated Molecular Patterns (DAMPs), a group
of mediators with intracellular functions that, when released
following cell death, act upon Pattern Recognition Receptors
(PRRs) (Piccinini and Midwood, 2010). Members of this family
include DNA and RNA fragments, uric acid, high mobility
group box 1 (HMGB1), S100 proteins, IL-1α and IL-33 among
others (Chen and Nuñez, 2010). Increased HMGB1 and IL-1α
levels have been observed in sputum from CF patients during
acute exacerbations, implicating this class of mediators in the
pathophysiology of the disease (Rowe et al., 2008; Colombo
et al., 2011). Furthermore, increased levels of HMGB1 can predict
the time to first pulmonary exacerbation, the number of future
exacerbations and the time-to-lung transplantation or death
(Liou et al., 2012).
IL-33 is the most recently discovered member of the IL-1
family of cytokines. Structural cells, such as endothelial cells,
epithelial cells and fibroblasts, express IL-33 (Schmitz et al.,
2005). IL-33 was proposed to play important functions in human
diseases (Palmer and Gabay, 2011). We recently reported an
increase of IL-33 in the nucleus of epithelial cells in lung explants
from CF patients (Roussel et al., 2013). These findings were
further supported by the discovery of the presence of IL-33 in
broncho-alveolar lavage fluid of clinically stable CF patients that
interestingly correlated negatively with Forced Vital Capacity, a
measure of pulmonary function (Tiringer et al., 2014).
Despite the implication of IL-33 in different pathologies,
the signals driving increases in IL-33 expression have not been
studied in detail. It was reported that signaling through Toll-
like receptors (TLRs) 2 and 4 could modulate IL-33 expression
in response to infection in human monocytes (Nile et al., 2010).
TLR2 and TLR4 both lead to the activation of the protein kinase
TGF-beta activated kinase 1 (TAK1) in a myeloid differentiation
primary response 88 (Myd88)-dependent manner. TAK1 in turn
leads to the activation of Mitogen-Activated Protein Kinases
(MAPKs) and nuclear factor kappa B (NFkB) signaling (Kawai
and Akira, 2010). Both extracellular signal-regulated kinase
(ERK)1/ERK2 and NFkB signaling require the activation of
inhibitor of kappa light polypeptide gene enhancer in B-cells
(IkB) kinase beta (IKKβ) by TAK1. IKKβ phosphorylates IkB
leading to its degradation, allowing the release and translocation
to the nucleus of NFkB (Alkalay et al., 1995). IKKβ also
phosphorylates NFkB1 p105, leading to the release and activation
of the protein kinase tumor progression locus-2 (TPL2), which in
turn phosphorylates and activatesMAPK kinase (MKK)1/MKK2,
the direct upstream activators of ERK1 and ERK2 (Beinke et al.,
2004). On the other hand, TAK1 also leads to the activation of
JNK and p38 MAPK (Goedert, 1997; Enslen, 1998).
In this manuscript we investigated the intracellular signaling
pathways responsible for increasing IL-33 expression in




5Z-7-oxozeaenol, NG25, BI605906, BIRB0796, and C1 were
kindly provided by Professor Sir Philip Cohen (MRC PPU,
University of Dundee, UK). PD184352 was bought from US
Biological (Swampscott, MA, USA). Flagellin, Pam3CSK4, LPS,
and the polyclonal antibodies against TLR2 (cat #pab-hstlr2),
TLR4 (cat #pab-hstlr4), and TLR5 (cat #pab-hstlr5) were
purchased from InvivoGen (San Diego, CA, USA). Antibodies
against p44/42 ERK MAPK (cat #9107) and phospho-ERK
Thr202/Tyr204 (cat #4370) were purchased from Cell Signaling
Technology. Recombinant human IL-1β was purchased from
R&D systems (Minneapolis, MN, USA). The clinical isolate of
Pseudomonas aeruginosa is the same isolate used previously
(Bérubé et al., 2010). CnT-BM.1 cell culture media and
A, B, and C supplements (CnT-17.S) were purchased from
CELLnTEC (Bern, Switzerland). Nuclear/cytoplasmic extract
kit was purchased from Active Motif (Carlsbad, CA, USA,
cat #40010).
Cell Culture
In this study we used two immortalized airway epithelial cell
lines: one expressing the most common mutation found in
CF, deletion of Phe508, termed UNC CF2, and referred to as
CFTRdelF508 in this manuscript and another cell line, which
expresses the wild type CFTR protein termed UNC N3 and
referred to as wild type CFTR that were kindly provided by
Dr. Scott Randell (The University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA; Fulcher et al., 2009).To enhance
cell adherence, cells were seeded onto PureCol pre-coated plates
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(Advanced BioMatrix San Diego, California, USA). Cells were
cultured in the medium CnT-17.S. All cells were maintained at
37◦C in 5 % CO2, 100% humidity. The medium was changed
every 48–72 h until cells reached 100% confluence. Cells were
then synchronized with the medium CnT-BM.1 overnight and
stimulated or infected as described.
Pseudomonas aeruginosa Infection
For acute bacterial infections, a clinical isolate of Pseudomonas
aeruginosa (mucoid strain) was grown in LB Broth (Fisher
Scientific) for 18 h at 37◦C with shaking at 250 rpm and diluted
to an optical density (OD) of 0.2 which corresponded to 3 × 109
colony forming units (CFU) per mL. CF and non-CF airway
epithelial cell lines were serum-starved overnight with CnT-
BM.1 (CELLnTEC, Bern, Switzerland) without supplements or
antibiotics. Bacteria were harvested by centrifugation, and re-
suspended in CnT-BM.1. Cells were infected with 9 × 106 CFU
of P. aeruginosa per well and incubated for 3 h at 37◦C. A 3 h
infection was selected because it was the earliest time point where
a significant induction of IL-33 could be detected.
RNA Extraction and Real-Time PCR
RNA Extraction
RNA extraction was performed using TRIzol reagent
(ThermoFischer Scientific). Briefly, after cell lysis with
TRIzol, chloroform was added to separate the aqueous and
by centrifugation at 12,000 × g at 4◦C. Isopropanol (Fisher
Scientific) as then added to precipitate RNA by centrifugation
for 10min at 12,000 × g at 4◦C. The RNA pellet was washed
with 75% ethanol and samples were then dried for 20min at
room temperature before being rehydrated in 5–10µl sterile
ribonuclease free water (Invitrogen). The diluted RNA quantified
using a nano-drop system (Thermo Scientific).
Reverse Transcription and Quantitative Real-Time
PCR
Potential DNA contamination from RNA samples was removed
with DNAseI (Fermentas, Burlington, Ontario, Canada).
Complementary DNA (cDNA) synthesis was then performed
using Maxima Reverse Transcriptase (Fermentas). After addition
of the mix containing reverse transcriptase, an RNAse inhibitor,
random hexamer, and a solution with the 4 deoxynulceotide
triphosphates, samples were incubated in a thermal cycler
(BioRadMy Cycler) as follows: 10min at 25◦C, 30min at 50◦C to
achieve full polymerase activity and 5min at 85◦C to inactivate
the enzyme.
For quantitative real-time PCR samples were assayed in Fast
96-well reaction plate (Applied Biosystems, Foster City, CA,
USA) with each condition containing 100 ng of cDNA in a
total volume of 2.5µL sterile water with 0.3µM of each forward
and reverse primer (Integrated DNA Technologies, Coralville,
IA), 5µl iTAQ SYBR Green Supermix with Rox (BioRad) as
well as 1.9µl sterile water. Quantitative real-time PCR (qRT-
PCR) was carried out in a Step-One-Plus machine (Applied
Biosystems, Foster City, CA). Each condition was normalized
to the housekeeping gene GAPDH. Relative fluorescence was
interpreted as fold induction from cycle threshold values using
the Pfaﬄ mathematical model.
Primer sequences are:
Gene Forward primer (5′–3′ ) Reverse primer (5′–3′ )
GAPDH AGC AAT GCC TCC TGC ACC ACC CCG GAG GGG CCA TCC ACA GTC
IL-33 CAA AGA AGT TTG CCC CAT GT AAG GCA AAG CAC TCC ACA GT
IL-1α ACC TCA CGG CTG CTG CAT TAC ATA TGG TCT TCA TCT TGG GCA GTC AC
HMGB1 GGA GAT CCT AAG AAG CCG AGA CAT GGT CTT CCA CCT CTC TGA
S100A9 AAA GAG CTG GTG CGA AAA GA TCA GCT GCT TGT CTG CAT TT
IL-8 GTG CAG TTT TGC CAA GGA GT CTC TGC ACC CAG TTT TCC TT
Cell Lysis and Immunoblotting
Following stimulation, cells were lysed in 80µL buffer containing
50mM Tris-HCl pH 7.5, 1mm EGTA, 1mm EDTA, 1%
(v/v) Triton x-100, 1mm sodium orthovanadate, 5mm sodium
pyrophosphate, 50mM sodium fluoride, 0.27M sucrose, 5mM
sodium pyrophosphate decahydrate, one complete mini protease
inhibitor mixture (Roche, Mannheim, Germany), and 2mm
DTT. Cell debris were separated from soluble proteins by
centrifugation for 5min at 4◦C at 12,000 × g. 70µL of
supernatants were then added to 23µL of loading buffer
(0.24mM Tris-HC, 8% SDS, 40% glycerol, and 36% distilled
water) containing 1X TCEP (Thermo Scientific). A portion of the
supernatant was retained for quantification using the Bradford
method.
Quantified and normalized proteins were boiled for 5min
at 95◦C. For each gel 30µg of protein were deposited per well
and separated by SDS-PAGE on a 10% Pro-pure Next Gel with
Pro-Pure Running Buffer (Amresco, Solon, OH) using BioRad
Powerpac HC (150V/3.0 A/300W) at 150V for 90min. The
proteins were then transferred from the gel to a nitrocellulose
membrane using ice-cold 1X NuPAGE transfer buffer (Fisher
Scientific), 10% methanol (v/v) for 35min at 100V. After
blocking with 5% BSA, the membranes were incubated with
primary antibodies for total ERK1/2 MAPK (1:500 dilution) and
for phosphor-ERK1/2 MAPK (1:1000 dilution) overnight at 4◦C.
Antibodies were washed off using TBS with 0.05% Tween 20
(Sigma Aldrich) and secondary antibodies of goat anti-rabbit IgG
DyLight™800 (Thermo Scientific, Cat #35571) and/or goat anti-
mouse IgG DyLight™680 (Thermo Scientific, Cat #35518) were
applied for 45min in the dark at room temperature at a dilution
of 1:15,000 in TBS 0.05% Tween. The membranes were washed
as before and the signal was detected and quantified using a Licor
Odyssey imaging system.
Quantification of Extracellular and
Intracellular IL-33 by ELISA
CFTRdelF508 cells were cultured in purecol-coated 6 well plates,
grown to 100% confluence and synchronized with CnT-BM.1
as described in Section Cell Culture. Cells were then pre-
incubated in the presence of different kinase inhibitors or
DMSO (vehicle) and infected with Pseudomonas aeruginosa
(MOI of 2) for 6 h. Supernatants were then harvested and
stored at −80◦C. Cytoplasmic proteins were obtained with the
Active Motif nuclear/cytoplasmic extract kit. Briefly, following
infection, cells were washed twice with ice-cold PBS containing
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phosphatase inhibitors, detached, and transferred to a pre-
chilled microcentrifuge tube. Cells were then precipitated by
centrifugation, supernatant was aspirated and the cell pellet was
resuspended in 1X hypotonic buffer. After 15min on ice, each
sample was vortexed for 10 s at the highest setting. Cell debris
were precipitated by centrifugation for 2min at 13,000 × g
at 4◦C and supernatants containing cytoplasmic proteins were
transferred to pre-chilled microcentrifuge tubes and stored at
−80◦C. IL-33 protein levels were measured by ELISA with the
human IL-33 DuoSet Elisa kit (R&D systems cat#DY3625-05).
Statistical Analysis
Results were analyzed with GraphPad Prism software (version
5.0), p-values less than 0.05 were considered to be significant.
Groups were compared by One-way ANOVA followed by
Bonferroni post-test comparing control vs. infected or infected
vs. the different inhibitors, ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p <
0.001. Figures generated from this analysis are presented as
means± standard error of the mean (SEM) of three independent
experiments.
RESULTS
P. aeruginosa Infection Increases IL-33
Expression in a CFTRdelF508 AEC Line
We have previously reported that diffusible material from
a P. aeruginosa clinical isolate (PsaDM) leads to increased
expression of IL-33 in CF airway epithelial cell lines (Roussel
et al., 2013). PsaDM, which contains exoproducts derived from
bacterial growth, mimics the chronic state of inflammation,
where bacterial cells are not in direct contact with the
epithelium (Worlitzsch et al., 2002). However, decline in lung
function has been associated with episodes of pulmonary
exacerbations (Sanders et al., 2010). Therefore, to mimic
pulmonary exacerbations, we determined whether IL-33 was also
upregulated during an acute bacterial infection. Similarly, to
our previous results, infection with live P. aeruginosa led to an
increase in IL-33 mRNA in a CFTRdelF508 AEC line but not
in its wild type counterpart (Figures 1A,B). We then wanted
to determine whether the increase of IL-33 mRNA led to an
increase in protein expression. IL-33 is mainly localized in the
nucleus of structural cells and is preferentially released upon
necrotic cell death (Roussel et al., 2008; Cayrol and Girard,
2009). To determine if the acute infection with P. aeruginosa
led to intracellular IL-33 accumulation vs. extracellular release,
we measured IL-33 protein levels both in the intracellular
and extracellular compartments. Interestingly, the increased
mRNA expression was accompanied by increased detection of
intracellular but not extracellular IL-33 following a 6 h infection
of CFTRdelF508 AECs with P. aeruginosa (Figures 1C,D).
CFTR Correction and Potentiation
Decrease IL-33 mRNA Expression in a
CFTRdelF508 AEC Line
Small molecule CFTR modulators are currently used as
pharmacological strategies to correct CFTR defects. Compounds
FIGURE 1 | Acute infection of a CFTRdelF508 cell line with Pseudomonas aeruginosa increases IL-33 expression. (A,B) CF airway epithelial cells
expressing the CFTRdelF508 mutation (A) and their wild-type counterparts (B) were infected with 9× 106 CFU of P. aeruginosa (MOI of 18) for 3 h and relative IL-33
gene expression was measured by qRT-PCR. (C,D) CFTRdelF508 cells were infected with Pseudomonas aeruginosa (MOI of 2) for 6 h. Supernatants were collected
and frozen before the cells were lysed in a hypotonic solution as described in the methods section. IL-33 levels in the intracellular (C) and extracellular (D) fractions
were quantified by ELISA. The dotted line at 3.75 pg/mL represents the limit of detection by ELISA. Results of three independent experiments were analyzed by
one-tailed t-tests, *p < 0.05, ***p < 0.001.
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that revert processing and folding defects are termed correctors
and those that increase channel gating and conductance
are termed potentiators (Lubamba et al., 2012).We used
this pharmacological approach to determine whether CFTR
function was directly related to IL-33 expression. CFTR channel
expression to the membrane was enhanced with the corrector
VX-809 (Lumacaftor) and its channel activity was increased with
the potentiator VX-770 (Ivacaftor) (Wainwright Claire, 2015).
Neither, the corrector nor the potentiator alone affected baseline
IL-33 expression (Figure 2A). Pre-treating CFTRdelF508 AECs
with either compound, or in combination, decreased the
P. aeruginosa-driven IL-33 (Figure 2A) and IL-8 (Figure 2B)
mRNA expression. These results support the notion that the
increase in IL-33 mRNA in CFTRdelF508 airway epithelial cells
in response to infection is due to CFTR malfunction as it was
previously shown for IL-8 (Veit et al., 2014).
P. aeruginosa-Driven IL-33 mRNA
Expression is Dependent on TLR2 and
TLR5
In monocytes, TLR2 and TLR4 activation was shown to increase
IL-33 expression (Nile et al., 2010). On the other hand, we
have shown that TLR5 and TLR2 are the two main receptors
activated by diffusible material from the clinical mucoid isolate
of P. aeruginosa used to stimulate cytokine production by AECs
(Beaudoin et al., 2012). To determine whether any of these
receptors could lead to an increase in IL-33 expression, we
stimulated CFTRdelF508 AECs with specific agonists for TLR2,
TLR4, and TLR5. IL-1β was used as a positive control for IL-33
upregulation (Onda et al., 1999). A significant increase of IL-33
mRNA was seen when CFTRdelF508 AECs were exposed to the
TLR5 agonist Flagellin and a trend to increase expression can be
observed upon exposure to the TLR1/TLR2 agonist Pam3CSK4
(Figure 3A). To identify the receptor(s) involved in transducing
P. aeruginosa signals, we prevented the activation of TLR2,
TLR4, and TLR5 using neutralizing antibodies. Neutralization
of both TLR2 and TLR5 blocked IL-33 mRNA upregulation
in response to P. aeruginosa (Figure 3B). In accordance with
low levels of TLR4 activation in AECs (Bérubé et al., 2009;
Beaudoin et al., 2012), no major role has been found for this
receptor, in contrast to monocytes/macrophages, where the TLR4
agonist LPS significantly increases IL-33 mRNA (Polumuri et al.,
2012). We have previously reported poor responsiveness to LPS
in other immortalized AECs (Bérubé et al., 2009; Beaudoin
et al., 2013). This could be due to a low level of expression of
TLR4 at the surface of AECs. Altogether, these results show that
the expression of IL-33 in CFTRdelF508 AECs exposed to P.
aeruginosa occurs via the activation of both TLR2 and TLR5.
P. aeruginosa-Driven IL-33 mRNA
Expression is Dependent on the
TAK1→IKKβ →TPL2→MKK1/MKK2
Signaling Pathway
The next step was to define the intracellular signaling
pathways involved in controlling the expression of IL-33.
TLR2 and TLR5 signal via the adaptor protein Myd88 as
described in the introduction. To study the involvement of
specific molecules activated downstream of Myd88, we used
the following pharmacological inhibitors: we prevented TAK1
activity using 0.25µM 5Z-7-oxozeaenol (Ninomiya-Tsuji et al.,
2003), IKKβ, activity using 7.5µM BI605906 (Clark et al.,
2011), TPL2 activity using 2µM C1 and MKK1/MKK2 activity
using 2µM PD184352 as previously reported (Martel et al.,
2013). Pre-incubating CFTRdelF508 AECs with these protein
kinase inhibitors showed that the activity of TAK1, IKKβ,
TPL2, and MKK1/MKK2 was required for IL-33 expression
FIGURE 2 | IL-33 mRNA upregulation in response to infection is dependent on CFTR channel function in CFTRdelF508 airway epithelial cells. (A,B)
CFTRdelF508 cells were incubated in the presence of the CFTR corrector VX-770 (1µM), the CFTR potentiator VX-809 (5µM) or a combination of both for 24 h. Cells
were then infected with P. aeruginosa (MOI of 18) for 3 h and IL-33 (A) and IL-8 expression (B) were measured by qRT-PCR. Results were analyzed by One-way
ANOVA followed by Bonferroni post-test comparing control vs. infected (#), infected vs. the corrector or potentiator (*) and control vs. the corrector or potentiator
alone. ###p < 0.001, ***p < 0.001.
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FIGURE 3 | IL-33 expression is regulated through TLR2 and TLR5-activated signaling following an acute infection with Pseudomonas aeruginosa.
(A) CFTRdelF508 cells were stimulated with the following TLR receptor agonists for 6 h: Pam3CSK4 (TLR1/2), 1µg/mL; LPS (TLR4), 1µg/mL; Flagellin (TLR5),
400 ng/mL and IL-1 β, 100 ng/mL. IL-33 mRNA expression was measured by qPCR (B). CFTRdelF508 cells were incubated with 20µg/mL of the neutralizing
antibodies against TLR2, TLR4, TLR5, and a combination of TLR2 and TLR5 for 30min. Cells were then infected with 9× 106 CFU of Psa (MOI of 18) for 3 h, in the
presence of the TLR neutralizing antibodies. IL-33 mRNA expression was measured by qPCR. Results from three independent experiments were analyzed by
One-way ANOVA followed by Dunnett (A) or Bonferroni (B) post-tests, *p < 0.05, #p < 0.05.
in CFTRdelF508 AECs (Figure 4A). Accordingly, ERK1/ERK2
phosphorylation was prevented by inhibitors of TAK1, IKKβ,
TPL2, and MKK1/MKK2 but only barely by the p38 MAPK
inhibitor BIRB0796 (Figure 4B).
P. aeruginosa Infection Increases IL-1α and
S100A9 mRNA Expression but Not that of
HMGB1
IL-33 is a member of the IL-1 family, functionally related to IL-
1α, since both are proposed to act as alarmins. P. aeruginosa
infection of CF AECs also increases IL-1α mRNA expression
(Figure 5A). To determine if this was specific to the IL-1
family, we also investigated the alarmins HMGB1 and S100A9.
HMGB1 like IL-1α is found in CF sputa (Rowe et al., 2008;
Colombo et al., 2011), whereas S100A9 is a part of Calprotectin,
a complex described as the Cystic Fibrosis protein in 1973
(Wilson et al., 1973).Whereas P. aeruginosa infection of CFAECs
led to increased S100A9 expression (Figure 5B), no increase
was detected for HMGB1 (Figure 5C). If anything, lower levels
were detected following infection (Figure 5C). IL-1α expression
was also regulated by the TAK1→IKKβ→TPL2→MKK1/MKK2
cascade (Figure 5A), whereas none of the protein kinase
inhibitors tested decreased the P. aeruginosa-driven S100A9
expression (Figure 5B).
DISCUSSION
In this manuscript we show that P. aeruginosa increases
the expression of IL-33 in a CFTRdelF508 airway epithelial
cell line via TLR2 and TLR5-mediated activation of the
TAK1→IKKβ→TPL2→MKK1/MKK2→ERK1/2 signaling
cascade (Figure 6).
In a previous study we had reported the presence of IL-33
in the epithelium of CF lungs and increased expression only
in CF AEC lines when challenged with P. aeruginosa diffusible
material (PsaDM) (Roussel et al., 2013), a challenge mimicking
the chronic inflammatory state. Interestingly, the presence of IL-
33 in Broncho-alveolar lavage fluid negatively correlated with
lung function in CF patients (Tiringer et al., 2014). Following
pulmonary exacerbations, CF patients undergo a net decline
in lung function (Sanders et al., 2010). Some studies have
attributed these episodes to the release of planktonic bacteria
from the biofilms colonizing CF lungs leading to acute episodes
of infection (Chattoraj et al., 2011). We report here that acutely
infecting a CFTRdelF508 AEC line with a live clinical isolate
of P. aeruginosa also led to IL-33 upregulation. As reported
for PsaDM (Roussel et al., 2013), this increased expression
of IL-33 occurs preferentially in the absence of functional
CFTR, the anion channel defective in CF. This is further
supported by decreased IL-33 expression when CFTRdelF508
AECs are pre-treated with a CFTR corrector (VX-809) and/or
potentiator (VX-770) before infection. Accordingly, IL-8 levels
were also decreased by these pre-treatments, further supporting
the link between CFTR malfunction and hyper-activation of the
inflammatory response (Veit et al., 2014). However, we cannot
completely rule out that VX-809 and VX-770 act through other
CFTR-independent mechanisms to regulate inflammatory gene
expression.
The molecular mechanisms responsible for this response in
CF AECs are unknown. Our results have shown that TLR-
mediated signaling regulates IL-33 expression in the context of
infection. However, TLR-signaling is activated in both non-CF
and CF AEC lines by PsaDM or live P. aeruginosa (Bérubé
et al., 2010; Beaudoin et al., 2012, 2013). One possibility is
the different levels of activation of TLR-signaling between non-
CF and CF AECs. We have shown that CF AECs are hyper
sensitive to a number of insults resulting in MAPK hyper-
activation (Bérubé et al., 2010). Therefore, there may exist a
threshold level required for IL-33 expression that is not reached
in non-CF AECs. Another possibility is the activity of a parallel
pathway that is permissive for IL-33 expression, which is not
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FIGURE 4 | Pseudomonas aeruginosa-driven IL-33 mRNA expression is dependent on the TAK1→IKKβ →TPL2→MKK1/MKK2 MAPK signaling
pathway. (A,B) CFTRdelF508 cells were pre-incubated for 1 h with DMSO (vehicle) or with one of the following inhibitors: PD184352, 2µM; BI605906, 7.5µM; C1,
2µM, or 5Z-7-oxozeaenol, 250 nM. Then, cells were infected with 9× 106 CFU of P. aeruginosa (MOI of 18) for 3 h (A) or 30min (B). (A) IL-33 mRNA expression was
analyzed by qRT-PCR. (B) CFTRdelF508 cells were pre-incubated with the p38 MAPK inhibitor BIRB0796, 0.1µM, (added as a control), the MKK1/2 inhibitor
PD184352, the TAK1 inhibitor 5Z-7-oxozeaenol and the TPL2 inhibitor C1. Cells were infected with P. aeruginosa and ERK1/ERK2 phosphorylation was measured by
immuno-blotting. (B) In addition to the TPL2 and MKK1/2 inhibitors, P. aeruginosa-induced ERK1/2 MAPK phosphorylation was assessed in the presence of another
TAK1 inhibitor NG25, 10µM and the IKKβ inhibitor BI605906. Results from 4A were compared by One-way ANOVA followed by Bonferroni post-hoc test, comparing
control vs. infected (#) or infected vs. the different inhibitors (*), *** or ###p < 0.001.
FIGURE 5 | Pseudomonas aeruginosa infection increases IL-1α and S100A9 mRNA expression but not that of HMGB1. CFTRDELF508 airway epithelial
cells were incubated in the presence of different kinase inhibitors as described in (A) and then infected with P. aeruginosa (MOI of 18) for 3 h. IL-1α (A), S100A9 (B),
and HMGB1 (C) gene expression was measured by qRT-PCR. Results were analyzed by One-way ANOVA followed by Bonferroni post-test comparing control vs.
infected (#) or infected vs. the different inhibitors (*), #p < 0.05, **p < 0.01, and ###p < 0.001.
activated in non-CF AECs, preventing IL-33 expression. Redox
balance seems to be impaired in CF AECs (Bérubé et al.,
2010; Duranton et al., 2012), favoring a higher oxidant burden,
which could activate such a parallel pathway. Interestingly, in
astrocytes, the presence of ROS is associated with IL33 expression
(Khan et al., 2014). Further, investigations are required to
elicit the mechanisms linking the absence of CFTR to IL-33
expression.
Our results using pharmacological inhibitors have
identified a key pathway required for IL-33 expression: the
TAK1→IKKβ→TPL2→MKK1/MKK2 cascade leading to
ERK1/ERK2 activation. Naturally, we cannot formally exclude
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FIGURE 6 | Signaling mechanisms regulating IL-33 expression. Binding
of bacterial PAMPs to TLR2 and TLR5 leads to the recruitment of adaptor
molecules that activate TAK1. TAK1 phosphorylates IKKβ, which in turn
phosphorylates the NFκ B subunit p105, leading to its dissociation from TPL2.
TPL2 is then released and is able to phosphorylate MKK1/MKK2, which
activate ERK1/ERK2 MAPKs resulting in the nuclear translocation ERK1/ERK2
and in the activation of transcription factors that increase IL-33 expression.
that some of these inhibitors have acted through other protein
kinases that they target “non-specifically.” This is the first time
that activation of the protein kinases TAK1, IKKβ, and TPL2
is linked to the expression of the pro-inflammatory cytokine
IL-33, illustrating further the importance of these protein
kinases to the regulation of inflammation in the context of
acute infection (Dumitru et al., 2000; Martel and Rousseau,
2014). ERK1/ERK2 role in IL-33 expression has previously been
shown in myofibroblasts stimulated with TNFα or IL-1β (Kobori
et al., 2010). Our data further strengthen the importance of the
activation of ERK1/ERK2 for expression of IL-33 in response to
inflammatory stimuli. It is well known that TAK1 signaling can
also result in the activation of p38 and JNKMAPKs. We have not
investigated these other TAK1-activated pathways in this study.
TAK1 and IKKβ activity are not only required for TPL2
activation but also lead to the activation of NFkB signaling.
We have not assessed directly whether NFkB is needed for
IL-33 expression in our CF AECs exposed to P. aeruginosa,
but in TNFα or IL-1β-stimulated myofibroblasts expressing a
dominant-negative form of IkB, IL-33 expression was impaired
(Kobori et al., 2010).
The expression of the related cytokine IL-1α, appears to be
very similarly regulated, however that of the unrelated alarmin
S100A9 occurs in a TAK1-indepent manner. Despite the high
level of transcripts, we did not detect increases in the expression
of HMGB1 by epithelial cells stimulated with P. aeruginosa. The
presence of HMGB1 in CF sputa (Rowe et al., 2008) may be due
to other cells such as macrophages (Jiang et al., 2007), which are
an abundant source of this alarmin, or neutrophils, which are
present in great numbers in CF sputum.
Overall, our results have defined a signaling cascade leading
to an increase of IL-33 expression in CF AECs in response to
an acute infection. We postulate that this increased expression
is linked to the diseased state of CF lungs and reducing IL-
33 expression may have benefits in limiting inflammation in
CF lungs. In that regard, targeting the protein kinases in
the TAK1→IKKβ→TPL2→MKK1/MKK2 signaling pathway
represents an attractive option.
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